RxDoctor Payments Data

Alena Apodaca

Family · Albuquerque, NMNPI 1619613023

Payments from drug & device makers

$431in general payments, 2019–2025

Across 20 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$127
  • Philips North America LLC$74
  • Amgen$70
  • Kiniksa Pharmaceuticals, Ltd.$52
  • Indivior Inc.$32
  • Alnylam Pharmaceuticals Inc.$21
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$41396%
  • Education$184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$431 in reported general payments places this provider in the 60th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$24,343
Medicare patients
247
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban162$179,288
EntrestoSacubitril/Valsartan192$176,773
EliquisApixaban137$141,087
FarxigaDapagliflozin Propanediol46$41,412
Repatha SureclickEvolocumab40$25,441
Metoprolol Succinate341$5,979
Atorvastatin Calcium290$5,570
Bumetanide78$1,975
Spironolactone191$1,951
Carvedilol157$1,860
Losartan Potassium161$1,812
Rosuvastatin Calcium91$1,775
Metoprolol Tartrate99$1,396
Flecainide Acetate33$1,381
Lisinopril123$1,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$127$176,773192 claims
AstraZenecaFarxiga$19$41,41246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →